Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - neisseria meningitidis group a polysaccharide 100 µg/ml (polysaccharide) - injection with diluent - 50µg/0.5ml - active: neisseria meningitidis group a polysaccharide 100 µg/ml (polysaccharide) excipient: thiomersal water for injection

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - neisseria meningitidis, group b (strain nz98/254) 25ug (as outer membrane vesicles (omv));   - suspension for injection - 25 mcg/0.5ml - active: neisseria meningitidis, group b (strain nz98/254) 25ug (as outer membrane vesicles (omv))   excipient: aluminium hydroxide histidine sodium chloride water for injection

Канада - английский - Health Canada

glaxosmithkline inc - recombinant neisseria meningitidis group b nhba fusion protein; recombinant neisseria meningitidis group b nada protein; recombinant neisseria meningitidis group b fhbp fusion protein; outer membrane vesicles (neisseria meningitidis group b nz98/254 strain) - suspension - 50mcg; 50mcg; 50mcg; 25mcg - recombinant neisseria meningitidis group b nhba fusion protein 50mcg; recombinant neisseria meningitidis group b nada protein 50mcg; recombinant neisseria meningitidis group b fhbp fusion protein 50mcg; outer membrane vesicles (neisseria meningitidis group b nz98/254 strain) 25mcg - vaccines

Соединенные Штаты - английский - NLM (National Library of Medicine)

merck sharp & dohme llc - haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen (unii: luy6p8763w) (haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen - unii:luy6p8763w) - haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen 7.5 ug in 0.5 ml - liquid pedvaxhib is indicated for routine vaccination against invasive disease caused by haemophilus influenzae type b in infants and children 2 to 71 months of age. liquid pedvaxhib will not protect against disease caused by haemophilus influenzae other than type b or against other microorganisms that cause invasive disease such as meningitis or sepsis. as with any vaccine, vaccination with liquid pedvaxhib may not result in a protective antibody response in all individuals given the vaccine. because of the potential for immune tolerance, liquid pedvaxhib is not recommended for use in infants younger than 6 weeks of age. (see precautions.) infants completing the primary two-dose regimen before 12 months of age should receive a booster dose (see dosage and administration). hypersensitivity to any component of the vaccine or the diluent. persons who develop symptoms suggestive of hypersensitivity after an injection should not receive further injections of the vaccine.

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - outer membrane vesicles (omv) from neisseria meningitidis group b containing the pora p1.4; neisseria meningitidis group b nhba fusion protein; neisseria meningitidis group b nada protein; neisseria meningitidis group b fhbp fusion protein - suspension for injection

Сингапур - английский - HSA (Health Sciences Authority)

becton dickinson holdings pte. ltd. - microbiology - intended for the identification of frequently isolated neisseria and haemophilus as well as several other fastidious bacteria.

Европейский союз - английский - EMA (European Medicines Agency)

sanofi pasteur msd, snc - polyribosylribitol phosphate from haemophilus influenzae type b as prp-ompc, outer membrane protein complex of neisseria meningitidis (outer membrane protein complex of the b11 strain of neisseria meningitidis subgroup b), adsorbed hepatitis b surface antigen produced in recombinant yeast cells (saccharomyces cerevisiae) - hepatitis b; meningitis, haemophilus; immunization - vaccines - procomvax is indicated for vaccination against invasive disease caused by haemophilus influenzae type b and against infection caused by all known subtypes of hepatitis b virus in infants 6 weeks to 15 months of age.,

Канада - английский - Health Canada

sanofi pasteur limited - meningococcal polysaccharide antigen group a; meningococcal polysaccharide antigen group c; meningococcal polysaccharide antigen group y; meningococcal polysaccharide antigen group w-135 - powder for solution - 500mcg; 500mcg; 500mcg; 500mcg - meningococcal polysaccharide antigen group a 500mcg; meningococcal polysaccharide antigen group c 500mcg; meningococcal polysaccharide antigen group y 500mcg; meningococcal polysaccharide antigen group w-135 500mcg - vaccines

Канада - английский - Health Canada

sanofi pasteur limited - meningococcal polysaccharide antigen group a; meningococcal polysaccharide antigen group c; meningococcal polysaccharide antigen group y; meningococcal polysaccharide antigen group w-135 - kit - 50mcg; 50mcg; 50mcg; 50mcg - meningococcal polysaccharide antigen group a 50mcg; meningococcal polysaccharide antigen group c 50mcg; meningococcal polysaccharide antigen group y 50mcg; meningococcal polysaccharide antigen group w-135 50mcg - vaccines

Канада - английский - Health Canada

glaxosmithkline inc - haemophilus influenzae type b-prp and tetanus toxoid conjugate (prp-t) - powder for solution - 10mcg - haemophilus influenzae type b-prp and tetanus toxoid conjugate (prp-t) 10mcg - vaccines